Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Share-based Compensation: 2021-2025

Historic Share-based Compensation for Biofrontera (BFRI) over the last 4 years, with Sep 2025 value amounting to $236,000.

  • Biofrontera's Share-based Compensation fell 18.06% to $236,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $961,000, marking a year-over-year increase of 1.37%. This contributed to the annual value of $1.0 million for FY2024, which is 2.49% down from last year.
  • As of Q3 2025, Biofrontera's Share-based Compensation stood at $236,000, which was up 26.20% from $187,000 recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Share-based Compensation registered a high of $551,000 during Q2 2022, and its lowest value of $129,000 during Q4 2021.
  • For the 3-year period, Biofrontera's Share-based Compensation averaged around $247,818, with its median value being $236,000 (2025).
  • Per our database at Business Quant, Biofrontera's Share-based Compensation skyrocketed by 196.90% in 2022 and then plummeted by 52.99% in 2023.
  • Quarterly analysis of 5 years shows Biofrontera's Share-based Compensation stood at $129,000 in 2021, then skyrocketed by 196.90% to $383,000 in 2022, then plummeted by 40.47% to $228,000 in 2023, then spiked by 31.14% to $299,000 in 2024, then decreased by 18.06% to $236,000 in 2025.
  • Its Share-based Compensation stands at $236,000 for Q3 2025, versus $187,000 for Q2 2025 and $239,000 for Q1 2025.